a neon research console / pentadecapeptide BPC-157
BPC-157 is a research pentadecapeptide measured across thirty preclinical repair studies and three small human pilots.
A neon-lit reading of the published record: what the studies genuinely established, where the human evidence stops, and how compounded access actually stands. Every quantitative claim is cited.
BPC-157 on one console
BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of a protein found in human gastric juice. Across roughly thirty preclinical studies it has accelerated tendon, ligament, muscle, gut, and other tissue repair, and a first formal pharmacokinetic study has now characterized how the molecule clears the body [2]. Three small human pilot studies exist; large controlled human trials do not [8].
This page reads that record as a console. The genuinely established preclinical findings get a clear signal: a fully transected rat Achilles tendon healed across biomechanical, functional, and microscopic measures after once-daily dosing [1]; the pro-angiogenic mechanism resolves to up-regulation of the VEGFR2 receptor with downstream Akt-eNOS signaling [3]. The honest gaps get flagged just as plainly: the evidence is overwhelmingly rodent, a large share of the foundational literature comes from a single research group, and no validated human pharmacokinetics exist [8]. BPC-157 is not an FDA-approved drug.
The sequence on the readout is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Molecular formula C62H98N16O22, molecular weight 1419.53 Da, CAS 137525-51-0. Everything below traces back to a numbered study on the full reference list with DOIs and PMIDs.
BPC-157 as a Pentadecapeptide: What the Molecule Is
BPC-157 the peptide is fifteen amino acids long — hence pentadecapeptide — and synthetic. It is a fragment of Body Protection Compound, a larger protein isolated from human gastric juice; BPC-157 itself does not circulate naturally, it is a stable synthesized sequence [5]. Researchers call it a "stable gastric pentadecapeptide" because it is reported to remain intact in gastric juice, which is unusual for a peptide and underlies the long-running interest in oral administration [2].
Structurally it carries no disulfide bonds and a high proline content, features the literature associates with its stability. It is frequently supplied as the acetate salt. The compound has appeared under several development designations over three decades — PL-10, PLD-116, and PL 14736 in an industrial inflammatory-bowel-disease program — which is why the same molecule shows up in the literature under different names [5]. None of those programs produced an approved finished drug.
It is not a hormone and not a steroid. It is reported to up-regulate the growth-hormone receptor in tendon fibroblasts, but that is a downstream signaling effect, not hormonal activity of the peptide itself [1].
What BPC-157 Is Studied For: Reported Effects in Preclinical Models
The breadth of the preclinical record is the headline. BPC-157 has been studied in tendon, ligament, muscle, bone, skin, nerve, and gastrointestinal injury models, and in liver, kidney, and lung protection during systemic insults [10]. The unifying framework is cytoprotection — protection of cells and tissues from injury — with angiogenesis as the most consistently reported mechanism [3].
The most measured single result is the transected rat Achilles tendon, where treated tendons recovered load-bearing capacity and showed better-organized collagen than untreated controls [1]. In the gut, the foundational work reduced gastric ulcer area, with an ulcer-formation inhibition ratio of 45.7-65.6% at the higher doses tested [4]. A 2024-2026 wave of reviews has catalogued this multifunctional activity and its possible medical applications [11].
What the record does not support is just as important. Common online claims — weight loss, muscle building in healthy subjects, testosterone increase — are not backed by the published evidence and should be treated skeptically. The studied effects are tissue repair and cytoprotection in injury models, not body recomposition. For the musculoskeletal data in detail, see the BPC-157 tendon repair research.
Where the human evidence stops
Three small human pilot studies make up the entire human dataset, and each is preliminary. A two-participant intravenous safety pilot infused up to 20 mg and reported no adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers — but with n=2, it establishes feasibility, not efficacy or population safety [7]. An uncontrolled intra-articular case series reported reductions across several types of knee pain [6]. A 12-patient intravesical pilot reported symptom resolution in most patients with interstitial cystitis [9].
That is the verdict on the first chapter, not the last. A 2025 narrative review concluded that despite broad preclinical support, human data remain extremely limited, rigorous large-scale trials are lacking, and BPC-157 should be considered investigational [8]. This site documents that literature — it does not extend it.
For the regulatory picture — FDA non-approval, the 2023 503A compounding category, WADA status, and how lawful compounded access works — see BPC-157 legal status and 503A category. For the most-asked questions, the common BPC-157 questions index covers twenty-five of them with cited answers.